131 related articles for article (PubMed ID: 8580268)
1. The effects of aminosalicylic acid derivatives on nitric oxide in a cell-free system.
Reynolds PD; Middleton SJ; Shorthouse M; Hunter JO
Aliment Pharmacol Ther; 1995 Oct; 9(5):491-5. PubMed ID: 8580268
[TBL] [Abstract][Full Text] [Related]
2. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
Bird HA
Br J Rheumatol; 1995 Nov; 34 Suppl 2():16-9. PubMed ID: 8535642
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of prostaglandin synthetase in human rectal mucosa.
Hawkey CJ; Lo Casto M
Gut; 1983 Mar; 24(3):213-7. PubMed ID: 6131017
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of leucocyte motility by drugs used in ulcerative colitis.
Rhodes JM; Bartholomew TC; Jewell DP
Gut; 1981 Aug; 22(8):642-7. PubMed ID: 6116649
[TBL] [Abstract][Full Text] [Related]
5. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Kimura I; Kumamoto T; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Oct; 48(10):1007-11. PubMed ID: 9825118
[TBL] [Abstract][Full Text] [Related]
6. Sulphasalazine and derivatives, natural killer activity and ulcerative colitis.
Gibson PR; Jewell DP
Clin Sci (Lond); 1985 Aug; 69(2):177-84. PubMed ID: 2866061
[TBL] [Abstract][Full Text] [Related]
7. Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine.
Allgayer H; Eisenburg J; Paumgartner G
Eur J Clin Pharmacol; 1984; 26(4):449-51. PubMed ID: 6428914
[TBL] [Abstract][Full Text] [Related]
8. Increased suppressor cell activity in inflammatory bowel disease.
Holdstock G; Chastenay BF; Krawitt EL
Gut; 1981 Dec; 22(12):1025-30. PubMed ID: 6119275
[TBL] [Abstract][Full Text] [Related]
9. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
[TBL] [Abstract][Full Text] [Related]
10. Sulfasalazine and 5-aminosalicylic acid inhibit contractile leukotriene formation.
Nielsen ST; Beninati L; Buonato CB
Scand J Gastroenterol; 1988 Apr; 23(3):272-6. PubMed ID: 2898806
[TBL] [Abstract][Full Text] [Related]
11. Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression.
Haskó G; Szabó C; Németh ZH; Deitch EA
Immunology; 2001 Aug; 103(4):473-8. PubMed ID: 11529938
[TBL] [Abstract][Full Text] [Related]
12. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine.
Szumlanski CL; Weinshilboum RM
Br J Clin Pharmacol; 1995 Apr; 39(4):456-9. PubMed ID: 7640156
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of sulphasalazine, 5-aminosalicylic acid and sulphapyridine on the humoral response to antigen in vivo.
Sheldon P; Pell P
Adv Exp Med Biol; 1995; 371B():905-8. PubMed ID: 7502923
[No Abstract] [Full Text] [Related]
14. Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis.
Roediger W; Schapel G; Lawson M; Radcliffe B; Nance S
Biochem Pharmacol; 1986 Jan; 35(2):221-5. PubMed ID: 2867767
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
Kles KA; Vavricka SR; Turner JR; Musch MW; Hanauer SB; Chang EB
Inflamm Bowel Dis; 2005 Mar; 11(3):253-7. PubMed ID: 15735431
[TBL] [Abstract][Full Text] [Related]
16. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
[TBL] [Abstract][Full Text] [Related]
17. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Kimura I; Kawasaki M; Matsuda A; Kataoka M; Kokurba Y
Arzneimittelforschung; 1998 Dec; 48(12):1163-7. PubMed ID: 9893931
[TBL] [Abstract][Full Text] [Related]
18. Effects of aminosalicylates and immunosuppressive agents on nitric oxide-dependent N-nitrosation reactions.
Grisham MB; Miles AM
Biochem Pharmacol; 1994 May; 47(10):1897-902. PubMed ID: 8204107
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological bases of therapy with 5-ASA].
Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
[No Abstract] [Full Text] [Related]
20. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation.
Rachmilewitz D; Karmeli F; Schwartz LW; Simon PL
Gut; 1992 Jul; 33(7):929-32. PubMed ID: 1353743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
